JINXIN TECHNOLOGY HOLDIN-ADR (NAMI) Fundamental Analysis & Valuation

NASDAQ:NAMI • US47760D1028

0.421 USD
-0.06 (-13.14%)
Last: Mar 9, 2026, 08:24 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This NAMI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

Overall NAMI gets a fundamental rating of 4 out of 10. We evaluated NAMI against 74 industry peers in the Diversified Consumer Services industry. NAMI is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. NAMI does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

5

1. NAMI Profitability Analysis

1.1 Basic Checks

  • In the past year NAMI was profitable.
NAMI Yearly Net Income VS EBIT VS OCF VS FCFNAMI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 0 20M -20M 40M 60M 80M

1.2 Ratios

  • NAMI's Return On Assets of 8.30% is fine compared to the rest of the industry. NAMI outperforms 79.73% of its industry peers.
  • NAMI has a better Return On Equity (16.95%) than 81.08% of its industry peers.
  • NAMI has a better Return On Invested Capital (13.77%) than 87.84% of its industry peers.
  • NAMI had an Average Return On Invested Capital over the past 3 years of 46.99%. This is significantly above the industry average of 10.83%.
  • The last Return On Invested Capital (13.77%) for NAMI is well below the 3 year average (46.99%), which needs to be investigated, but indicates that NAMI had better years and this may not be a problem.
Industry RankSector Rank
ROA 8.3%
ROE 16.95%
ROIC 13.77%
ROA(3y)30.62%
ROA(5y)N/A
ROE(3y)91.51%
ROE(5y)N/A
ROIC(3y)46.99%
ROIC(5y)N/A
NAMI Yearly ROA, ROE, ROICNAMI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 50 100 150

1.3 Margins

  • NAMI's Profit Margin of 4.99% is fine compared to the rest of the industry. NAMI outperforms 63.51% of its industry peers.
  • The Operating Margin of NAMI (6.67%) is better than 62.16% of its industry peers.
  • With a Gross Margin value of 28.78%, NAMI is not doing good in the industry: 64.86% of the companies in the same industry are doing better.
Industry RankSector Rank
OM 6.67%
PM (TTM) 4.99%
GM 28.78%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NAMI Yearly Profit, Operating, Gross MarginsNAMI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. NAMI Health Analysis

2.1 Basic Checks

  • NAMI has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • The number of shares outstanding for NAMI has been reduced compared to 1 year ago.
  • NAMI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NAMI Yearly Shares OutstandingNAMI Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 20M 40M 60M
NAMI Yearly Total Debt VS Total AssetsNAMI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • An Altman-Z score of 2.52 indicates that NAMI is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • NAMI has a better Altman-Z score (2.52) than 67.57% of its industry peers.
  • NAMI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.52
ROIC/WACC1.83
WACC7.54%
NAMI Yearly LT Debt VS Equity VS FCFNAMI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • A Current Ratio of 1.67 indicates that NAMI should not have too much problems paying its short term obligations.
  • NAMI has a better Current ratio (1.67) than 68.92% of its industry peers.
  • A Quick Ratio of 1.62 indicates that NAMI should not have too much problems paying its short term obligations.
  • With a decent Quick ratio value of 1.62, NAMI is doing good in the industry, outperforming 70.27% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.67
Quick Ratio 1.62
NAMI Yearly Current Assets VS Current LiabilitesNAMI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. NAMI Growth Analysis

3.1 Past

  • The earnings per share for NAMI have decreased strongly by -35.15% in the last year.
  • NAMI shows a small growth in Revenue. In the last year, the Revenue has grown by 7.00%.
EPS 1Y (TTM)-35.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)7%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NAMI Yearly Revenue VS EstimatesNAMI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 100M 200M 300M 400M

More info and screens

Find the best growth stocksShow best growing peers

3

4. NAMI Valuation Analysis

4.1 Price/Earnings Ratio

  • NAMI is valuated cheaply with a Price/Earnings ratio of 4.21.
  • 94.59% of the companies in the same industry are more expensive than NAMI, based on the Price/Earnings ratio.
  • NAMI's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.46.
Industry RankSector Rank
PE 4.21
Fwd PE N/A
NAMI Price Earnings VS Forward Price EarningsNAMI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, NAMI is valued cheaper than 94.59% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 2.89
NAMI Per share dataNAMI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.2 0.4 0.6 0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NAMI Dividend Analysis

5.1 Amount

  • NAMI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NAMI Fundamentals: All Metrics, Ratios and Statistics

JINXIN TECHNOLOGY HOLDIN-ADR

NASDAQ:NAMI (3/9/2026, 8:24:21 PM)

0.421

-0.06 (-13.14%)

Chartmill FA Rating
GICS IndustryGroupConsumer Services
GICS IndustryDiversified Consumer Services
Earnings (Last)12-22
Earnings (Next)04-13
Inst Owners0%
Inst Owner Change-97.85%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap28.78M
Revenue(TTM)406.40M
Net Income(TTM)20.27M
AnalystsN/A
Price TargetN/A
Short Float %0.02%
Short Ratio0.68
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 4.21
Fwd PE N/A
P/S 0.49
P/FCF N/A
P/OCF N/A
P/B 1.66
P/tB 3.78
EV/EBITDA 2.89
EPS(TTM)0.1
EY23.75%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.86
BVpS0.25
TBVpS0.11
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.76
Profitability
Industry RankSector Rank
ROA 8.3%
ROE 16.95%
ROCE 17.43%
ROIC 13.77%
ROICexc 17.55%
ROICexgc 38.89%
OM 6.67%
PM (TTM) 4.99%
GM 28.78%
FCFM N/A
ROA(3y)30.62%
ROA(5y)N/A
ROE(3y)91.51%
ROE(5y)N/A
ROIC(3y)46.99%
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)59.48%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover1.66
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.67
Quick Ratio 1.62
Altman-Z 2.52
F-ScoreN/A
WACC7.54%
ROIC/WACC1.83
Cap/Depr(3y)131.41%
Cap/Depr(5y)N/A
Cap/Sales(3y)7.53%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-35.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)7%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-66.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-182%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-54.56%
OCF growth 3YN/A
OCF growth 5YN/A

JINXIN TECHNOLOGY HOLDIN-ADR / NAMI FAQ

Can you provide the ChartMill fundamental rating for JINXIN TECHNOLOGY HOLDIN-ADR?

ChartMill assigns a fundamental rating of 4 / 10 to NAMI.


What is the valuation status for NAMI stock?

ChartMill assigns a valuation rating of 3 / 10 to JINXIN TECHNOLOGY HOLDIN-ADR (NAMI). This can be considered as Overvalued.


What is the profitability of NAMI stock?

JINXIN TECHNOLOGY HOLDIN-ADR (NAMI) has a profitability rating of 5 / 10.


What is the financial health of JINXIN TECHNOLOGY HOLDIN-ADR (NAMI) stock?

The financial health rating of JINXIN TECHNOLOGY HOLDIN-ADR (NAMI) is 7 / 10.